Tirzepatide attenuates LPS-induced acute lung injury in mice by activating AMPK and suppressing NF-κB
Background
Sepsis-associated acute lung injury (ALI) is a severe condition characterized by uncontrolled systemic inflammation, significant disruption of the redox balance, and impaired pulmonary function, leading to high morbidity and mortality. Current therapeutic strategies often fall short in effectively managing the complex interplay of inflammatory and oxidative processes. Tirzepatide, a synthetic dual GLP-1 and GIP receptor agonist, is known for its potent metabolic-regulating properties and emerging anti-inflammatory effects. This study investigated its potential protective role in LPS-induced ALI, exploring its underlying mechanisms to address this critical unmet need.
Study Design
Researchers employed a murine model of LPS-induced acute lung injury (ALI) to evaluate the protective effects of Tirzepatide. For mechanistic validation, the AMPK inhibitor Compound C was co-administered. Lung tissue samples underwent histopathological assessment and injury scoring using hematoxylin and eosin (H&E) staining. Aquaporin 5 expression, a marker of lung edema, was analyzed via immunohistochemistry. Further, Western blot and real-time PCR techniques were utilized to quantify protein and gene expression levels associated with the AMPKα/NF-κB p65 signaling pathways, along with markers of oxidative stress and inflammation.
Results
Tirzepatide demonstrated significant protective effects against LPS-induced ALI. It effectively reduced oxidative stress, evidenced by decreased malondialdehyde (MDA) levels while concurrently increasing catalase (CAT) and glutathione (GSH) levels in lung tissue. In bronchoalveolar lavage fluid (BALF), Tirzepatide attenuated inflammatory cell infiltration and lowered concentrations of pro-inflammatory cytokines. Furthermore, Tirzepatide substantially mitigated lung tissue pathological damage and alleviated pulmonary edema, confirmed by a reduced wet/dry weight ratio and normalized Aquaporin 5 expression at both mRNA and protein levels. It also improved critical lung function parameters, including dynamic compliance (Cdyn), peak expiratory flow (PEF), and airway resistance (RAW). Mechanistically, Tirzepatide activated the AMPK signaling pathway and suppressed NF-κB p65 phosphorylation, effects that were notably reversed by the AMPK inhibitor Compound C.
Key Findings
- Tirzepatide reduced oxidative stress by decreasing MDA and increasing CAT/GSH levels in lung tissue.
- It attenuated inflammatory cell infiltration and lowered pro-inflammatory cytokine concentrations in BALF.
- Tirzepatide significantly mitigated lung tissue pathological damage and alleviated pulmonary edema.
- Lung function parameters, including Cdyn, PEF, and RAW, were improved by Tirzepatide.
- Mechanistically, Tirzepatide activated the AMPK pathway and suppressed NF-κB p65 phosphorylation.
Why It Matters
This research highlights a novel, non-metabolic therapeutic potential for Tirzepatide in acute inflammatory conditions like acute lung injury (ALI). For clinicians and biohackers, this suggests that GLP-1/GIP agonism, specifically via Tirzepatide, might offer protective benefits beyond its established roles in metabolic disease, potentially mitigating severe inflammatory responses. The identification of the AMPK/NF-κB pathway as a key mechanism provides a clearer understanding of its anti-inflammatory actions. This finding could pave the way for repurposing Tirzepatide or developing new strategies for sepsis-associated ALI, though human clinical trials are essential to translate these preclinical observations into usable protocols. It expands the known therapeutic scope of this dual agonist, suggesting broader applications for its anti-inflammatory properties.
tirzepatide
acute lung injury
sepsis
inflammation
oxidative stress
ampk